Company intelligence / Profile preview
CuraVac
Belgiumcuravac.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
CuraVac’s lead candidate, CV-MG, a therapeutic vaccine/targeted active therapy for myasthenia gravis, has completed a phase 1B clinical trial demonstrating an excellent safety profile. The company is preparing to initiate a phase 2 efficacy trial with an improved formulation (CV-MG02). The approach is based on inducing neutralizing antibodies against autoantibodies targeting the acetylcholine receptor, aiming to restore neuromuscular function without broadly suppressing the immune system.
- Therapeutic areas
- EndocrinologyNeurologyImmunology
- Modalities
- PeptidesVaccineActive targeted immunotherapyTargeted active therapyBiologic (as a broad category)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on CuraVac.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CuraVac.